Shan-Shan Guo

Adjuvant sintilimab-capecitabine versus capecitabine alone in locoregionally advanced nasopharyngeal carcinoma with suboptimal response to induction chemotherapy: An open-label, randomized, controlled, phase 2 trial.

Li-Ting Liu, Hai‐Qiang Mai, Q X Chen, Lin-Quan Tang et autres

LBA6005 Background: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is the current standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC); however, patients with a suboptimal response to IC remain at high risk of disease progression. Although adjuvant capecitabine has demonstrated efficacy …

cn (code pays fourni par la source)

Data from GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study

Lin-Quan Tang, Sai-Lan Liu, Muh-hwa Yang, Hui-Ching Wang et autres

AbstractPurpose: GFH018 is a novel TGF-β type I receptor inhibitor, which has been shown to potentiate the antitumor effect of anti–PD-1/PD-L1 blockade. This study aimed to evaluate the safety and efficacy of GFH018 plus toripalimab in patients with recurrent/metastatic (R/M) nasopharyngeal carcinoma …